Attached files
| file | filename |
|---|---|
| 8-K - FORM 8-K - AERIE PHARMACEUTICALS INC | d201981d8k.htm |
 Aerie
Pharmaceuticals, Inc. July 13, 2016
Building a Major Ophthalmic Pharmaceutical Company Exhibit 99.1 |
 2 Important Information Any discussion of the potential use or expected success of our product candidates is subject to our
product candidates being approved by regulatory authorities. In addition, any
discussion of clinical trial results
for Rhopressa (netarsudil ophthalmic solution) 0.02% relate to the results in its first Phase 3 registration trials, Rocket 1 and Rocket 2, and for Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% relate to the results in its Phase 2b clinical trial. The information in this presentation is current only as of its date and may have changed or may change
in the future. We undertake no obligation to update this information in light of new
information, future events or otherwise. We are not making any
representation or warranty that the information in this presentation is
accurate or complete. Certain statements in this presentation are
“forward-looking statements” within the meaning of the federal securities laws. Words such as “may,” “will,” “should,” “would,” “could,” “believe,”
“expects,” “anticipates,” “plans,”
“intends,” “estimates,” “targets,” “projects,” “potential” or similar expressions are intended to identify these forward-looking statements. These statements are based on the Company’s current plans
and expectations. Known and unknown risks, uncertainties and other factors could cause
actual results to differ materially from those contemplated by the
statements. In evaluating these statements, you should specifically
consider various factors that may cause our actual results to differ materially from any forward-looking statements. In particular, the preclinical research discussed in this presentation is
preliminary and the outcome of such preclinical studies may not be predictive of the
outcome of later trials. Any future clinical trial results may not
demonstrate safety and efficacy sufficient to obtain regulatory approval
related to the preclinical research findings discussed in this presentation. These risks and uncertainties are described more fully in the quarterly and annual reports that we file with the SEC,
particularly in the sections titled “Risk Factors” and
“Management’s Discussion and Analysis of Financial Condition
and Results of Operations.” Such forward-looking statements only speak as of the date they are made. We undertake no obligation to publicly update or revise any forward-looking statements,
whether because of new information, future events or otherwise, except as otherwise
required by law. TM
TM |
 3 Aerie Late Stage IOP–Lowering Products Pre-Clinical Research • Rhopressa™ • Potential for disease modification and neuroprotection
• AR-13154 • Significant lesion size reduction in wet AMD • Drug Delivery - Front and back of the eye Data on File • Rhopressa™ (netarsudil ophthalmic solution) 0.02%
• Inhibits ROCK, NET, lowers EVP, targets diseased tissue • NDA filing expected Q3 2016 • Roclatan™ • Fixed combination of Rhopressa™ and latanoprost • Two P3’s in process; topline efficacy expected Q3 2016 Aerie – Building a Major Ophthalmic Pharmaceutical Company (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%
|
 FY 2015
U.S. Glaucoma Market = $2.5B; 34M TRx Market Share in TRx
2015 US GLAUCOMA MARKET
Once Daily 2-3 Times Daily 9% 8% 35% 13% 15% 10% 8% Bimatoprost Travoprost Latanoprost BB Fixed Combo AA CAI PGA: Prostaglandin Analogue; BB: Beta Blocker; AA: Alpha Agonist; CAI: Carbonic Anhydrase Inhibitor
Source: IMS MIDAS. IMS NPA
4 Non-PGA Market PGA Market |
 5 Rhopressa™ and Roclatan™ Expected Aerie Market
Positioning *Data on file
Triple-Action*
Rhopressa™
Quadruple-Action*
Roclatan™
Commercialization Strategy – Now Entering Launch Mode North America : ~100 sales reps targeting ~10,000 high prescribers Europe and Japan: Currently exploring opportunities Future drug of choice as adjunctive therapy to PGAs when additional IOP lowering is desired Future drug of choice for patients requiring maximal IOP lowering |
 6 Rhopressa™ Trials for Q3 2016 NDA Submission “Rocket 1” 90-Day Efficacy Registration Trial U.S. Rhopressa™ 0.02% QD ~200 patients timolol BID ~200 patients (Total enrollment: 411 patients) “Rocket 2” One Year Safety (3 Mo. Interim Efficacy) Registration Trial U.S. Rhopressa™ 0.02% QD ~230 patients Rhopressa™ 0.02% BID ~230 patients timolol BID ~230 patients (Total enrollment: 756 patients) ClinicalTrials.gov Identifier: NCT02207491, NCT02207621 |
 7 Rhopressa™ Trials for IND and EU Filing; Not Needed for NDA Filing ClinicalTrials.gov Identifier: NCT02246764, NCT02558374 “Rocket 4” 3 Month Efficacy 6 Month Safety Rhopressa™ 0.02% QD ~350 patients timolol BID ~350 patients “Rocket 3” One Year Safety Registration Trial Canada Rhopressa™ 0.02% QD ~90 patients Rhopressa™ 0.02% BID ~90 patients timolol BID ~60 patients |
 8 Rocket 2 and Rocket 1 Performance Maximum Baseline IOP <25 mmHg *Data on File Rocket
2 Rocket 1 |
 9 Rocket 2: 12 Month 8am IOP Efficacy Safety Population, Completed Patients (<27 mmHg) Difference in 8am mean IOP from Day 90 (Month 3) to Month 12: Rhopressa TM QD: Full population: +0.1 mmHg Subset analyses: -0.3 to +0.3 mmHg Timolol BID: Full population: +0.5 mmHg Subset analyses: +0.1 to +1.4 mmHg *Data on File Day 90 Month 12 AR-13324 0.02% q.d. (n=118) BL W2 W6 M3 M6 M9 M12 |
 10 Rocket 2: Safety/Tolerability Overview of Rhopressa QD (Interim 12-Month) * Incidence of conjunctival hyperemia ~50% including baseline at ~20% ** The updated term for these deposits based on recent MedDRA coding revisions There were no drug-related serious adverse events (SAEs) No new adverse events introduced over the twelve-month period The most common adverse event was conjunctival hyperemia with ~50% incidence*, the majority mild Other ocular AEs AEs occurring in ~5-23% of patients included: conjunctival hemorrhage, corneal deposits (verticillata**), blurry vision and reduced visual acuity TM |
 11 Rhopressa TM Adverse Events Summary Source: Aerie Pharmaceuticals Rhopressa TM Update public SEC filing, March 17, 2016 * The updated term for these deposits based on MedDRA coding revisions Hyperemia – absent or sporadic for 90% of patients - only 10% of patients had hyperemia AE at all 6 study visits Conjunctival Hemorrhage – sporadic subconjunctival petechiae - none noted at month 12 visit Corneal Deposits (verticillata*) – asymptomatic non-toxic lipid deposits - high resolution rate Visual Acuity Reduced – sporadic, mostly single visit, only one eye - incidence reduced over time Vision Blurred – sporadic and significantly reduced over 12 months |
 12 When Present, 80% of Rhopressa TM QD Hyperemia Graded as Mild Grade Image Description 0 None/Normal 1 Mild 2 Moderate 3 Severe ++ Data on File based on Rocket 2 Interim 12-month safety For illustrative purposes only |
 13 Conjunctival Hemorrhage Using Biomicroscopy Evaluation • Subconjunctival petechiae seen sporadically in Rhopressa TM Rocket studies • MedDRA coded to conjunctival hemorrhage • No conjunctival hemorrhages noted at month 12 visit ++ Data on File – an example of conjunctival hemorrhage courtesy of investigator from Rocket 2 |
 14 Adjunctive Therapy Product Safety Comparison Source: Aerie Pharmaceuticals Rhopressa TM Update public SEC filing, March 17, 2016 Rhopressa TM QD – no systemic absorption and no serious adverse events
Beta-Blockers BID (Timolol) – systemic absorption and contraindicated for patients with cardiopulmonary disease – about half of patients over 65 Alpha Agonists TID – systemic absorption, hyperemia and allergic conjunctivitis, somnolence and eye pruritus Carbonic Anhydrase Inhibitors TID – systemic absorption, sulfonamide reactions, severe renal failure, dysgeusia Prescriptions for Currently Marketed Adjunctive Therapies Represent Nearly Half of the Entire U.S. Glaucoma Market |
 15 Aerie Perspective on Rhopressa TM Advantages* *Data on file **Preclinical data presented at American Glaucoma Society 2016 Annual Meeting and available on Aerie
website Clinical:
Demonstrated once-daily IOP lowering in Phase 3 trials
Triple mechanism of action
Potential PGA synergy More consistent IOP-lowering across baselines than PGAs and timolol No systemic side effects Research: Targets diseased trabecular meshwork in glaucoma Potential to preserve health of trabecular outflow pathway** Potential to promote retinal ganglion cell survival and axon regeneration** |
 16 Roclatan™ Phase 2b Clinical Trial Design Phase 2b Protocol Roclatan™ 0.01% vs. Roclatan™ 0.02% vs. Rhopressa™ 0.02% vs. latanoprost All Dosed QD PM ~300 Patients 28 Days Primary efficacy endpoint: Mean diurnal IOP on Day 29 Two concentrations of Roclatan™ vs. Rhopressa™ 0.02% and latanoprost Trial design follows FDA requirement for fixed-dose combination |
 17 Mean IOP at Each Time Point Primary Efficacy Measure 0.02% Roclatan™ Achieved Statistical Superiority Over Individual Components at All Time Points (p<0.001) Roclatan™ Phase 2b, Intent to Treat 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 Pre- 8AM 8AM 10AM 4PM 8AM 10AM 4PM 8AM 10AM 4PM 8AM 10AM 4PM 8AM Study Qual 1 Baseline Day 8 Day 15 Day 29 Day 30 0.02% Rhopressa™ (n=78) 0.005% Latanoprost (n=73) 0.02% Roclatan™ (n=72) |
 18 Roclatan™ Phase 2b Responder Analysis: Goal is to Achieve Lowest IOP Possible Day 29: % of Patients with IOP Reduced to 20 mmHg or Lower Source: Lewis RA, Levy B, Ramirez N, Kopczynski CC, Usner DW, Novack GD for the PG324-CS201 Study Group. Fixed-dose combination of
AR-13324 and latanoprost: a double-masked, 28-day,
randomised, controlled study in patients with open-angle glaucoma or ocular hypertension. Br J Ophthalmol 2015;0:1–6. doi:10.1136/bjophthalmol-2015-306778 10% 21% 24% 39% 65% 8% 18% 29% 47% 72% 38% 46% 57% 69% 91% 0% 20% 40% 60% 80% 100% 15 mmHg 16 mmHg 17 mmHg 18 mmHg 20 mmHg IOP on Treatment 0.005% Latanoprost (n=73) 0.02% Rhopressa™ (n=78) 0.02% Roclatan™ (n=72) |
 19 Roclatan™ Registration Trial Design “Mercury 1”* One Year Safety (3 Mo. Interim Efficacy) Registration Trial U.S. “Mercury 2” 90-Day Efficacy Registration Trial U.S. and Canada “Mercury 3” 6 Mo. Efficacy and Safety Registration Trial Europe Roclatan™ QD ~230 patients Rhopressa™ 0.02% QD ~230 patients latanoprost QD ~230 patients Roclatan™ QD ~230 patients Comparator (TBD) ~230 patients *ClinicalTrials.gov Identifier: NCT02558400 Roclatan™ QD ~230 patients Rhopressa™ 0.02% QD ~230 patients latanoprost QD ~230 patients |
 20 Roclatan TM Path Forward * Data on file. FDA guidance, presentations and sponsor meetings. Trial design follows FDA requirement* for fixed dose combination
- Superiority of combination over each individual component
- Statistically significant difference at measured time
points - Higher combo efficacy vs. components of at least ~1-3 mmHg, as previously accepted by FDA for product approval - Favorable safety profile Roclatan Phase 2b safety profile, including hyperemia, was consistent with Rhopressa - latanoprost AEs not additive Simbrinza® (FDC) was approved in 2013 with AEs of both AA’s and CAI’s, and also did not achieve the efficacy guidance at all time points If Mercury 1 and Mercury 2 are
Successful Roclatan TM NDA Filing Expected 2H 2017 TM TM |
 21 Expanding Franchise to Europe and Japan Europe Current clinical plan expected to satisfy EU regulatory requirements (including Rocket 4 for Rhopressa and Mercury 3 for Roclatan ) Establishing KOL relationships in top 5 countries Targeting completion of EU commercialization strategy by YE16 Expect to file EU MAA for Rhopressa™ by approximately mid-2017 Japan Discussions regarding potential Rhopressa™ out-licensing are ongoing Also preparing to advance clinical development on our own Conferring with PMDA to confirm path to approval Prepared to secure a CRO relationship in 2016 to conduct trials TM TM |
 22 Enhancing the Aerie Pipeline Rhopressa TM preclinical findings* Disease modification potential – anti-fibrotic and increased perfusion Neuroprotection potential From our proprietary molecule library – preclinical AR-13154 for wet AMD and diabetic retinopathy Drug Delivery opportunities – front of the eye (Glaucoma) and back of the eye (e.g., AR-13154 for wet AMD) * Data on file |
 23 AR-13324* May Have Anti-Fibrotic Activity in Human Trabecular Meshwork Cells Control TGF 2 (8ng/ml) TGF 2 (8 ng/ml) + AR-13324 (500nM) P. Vasantha Rao, Duke University * Active ingredient of Rhopressa™; TGF 2: Transforming growth factor 2; SMA: Smooth muscle actin; FSP1: Fibroblast-specific protein 1 • Pattabiraman, Padmanabhan P., et. Al., (2015 March) “Effects of Rho Kinase inhibitor AR-13324 on actin cytoskeleton and TGF 2 and CTGF- induced fibrogenic activity in Human Trabecular Meshwork Cells”. AR-13324 Blocks TGF-beta-Induced Expression of Fibrosis Proteins in Human TM Cells |
 24 + Netarsudil Control Netarsudil* Causes Expansion of TM Tissue, Opening Spaces for Increased Outflow Dan Stamer (Duke), Haiyan Gong (Boston University) TM: Trabecular Meshwork SC: Schlemm’s Canal Control = buffered saline solution *Active ingredient of Rhopressa™ Increasing Trabecular Outflow, Reducing Fibrosis Could Stop Degeneration of Outflow Tissues in Glaucoma |
 25 + AR-13324 Control AR-13324* May Increase Perfusion of
Human TM Outflow Tissues Dan Stamer (Duke), Haiyan Gong (Boston University) AR-13324’s Ability to Increase Perfusion of Human TM Ex Vivo Supports Potential to Provide More Nutrients and Antioxidants to the TM Left (OS) and right (OD) eyes perfused with fluorescent microbeads Control = buffered saline solution *Active ingredient of Rhopressa™ ** Percent Effective Filtration Area 0.00 10.00 20.00 30.00 40.00 50.00 60.00 Anterior PEFA** (%) AR-13324 Control |
 26 Rhopressa TM Promotes RGC Survival and Axon Regeneration Following Optic Nerve Injury *Manuscript in revision for publication; reproduced with permission Jeffrey Goldberg (Stanford University)* Distance from crush site ( m) Axon Regeneration RGC Survival Retina Location Rat optic nerve crush model AR-13324 (n=3) Placebo (n=3) AR-13324 (n=3) Placebo (n=3) |
 27 Laser-induced choroidal neovascularization (CNV) in rats Compounds delivered by intravitreal injection AR-13154 vs. Eylea in Preclinical AMD Model ROCK/JAK2/PDGFR Inhibitor AR-13154 Numerically More Effective than Eylea ® in Rat Model of AMD ** * * p<0.05 vs. Saline ** p<0.001 ® Data on file 20000 30000 40000 50000 60000 70000 80000 90000 100000 110000 Saline n=49 0.06 ug/mL AR -13154 n=28 0.6 ug/mL AR -13154 n=25 6 ug/mL AR -13154 n=25 800 ug/mL Eylea n=20 Total CNV Lesion Area (Day 21) |
 28 Topical AR-13154(S) Provides Added Efficacy to Eylea in Proliferative Diabetic Retinopathy Model Oxygen-induced retinopathy model of PDR (mouse) 0.06% AR-13154(S) delivered topically from P12 to P17 Eylea delivered IP Confirms AR-13154(S) potential as effective adjunct to anti-VEGF therapies -37% -34% -57% ** *** *** *** *** p < 0.0001 vs. vehicle control ** p < 0.001 vs. monotherapy 0% 20% 40% 60% 80% 100% 120% Vehicle Control (n=55) AR -13154(S) topical (n=28) Eylea 1mg/kg IP (n=26) AR -13154(S) + Eylea (n=18) Total Neovascular Area |
 29 Summary • Key Clinical Priorities • Rhopressa TM : NDA filing expected Q3 2016 Rocket 4 in process (not required for NDA filing) • Roclatan TM : Mercury 1 and 2 in process Mercury 1 topline efficacy expected Q3 2016 • Research Initiatives • Rhopressa™ disease modification, neuroprotection, sustained release
• AR-13154 potential in wet AMD, etc. • Evaluating Aerie’s 3,000+ proprietary molecules • Business Development Opportunities • Drug delivery opportunities for front and back of the eye Note: As of March 31, 2016, Aerie had $130 million of cash and marketable securities on the balance sheet |
 30 2016 2017 Rhopressa TM and Roclatan TM Key Milestones Q3-2017: Roclatan™ P3 Mercury 1 Topline safety (12 mos) 2H-2017: Roclatan™ NDA filing expected 1H-2017: Roclatan™ P3 Mercury 3 (EU) to be initiated Q1-2016: Rhopressa™ Rocket 2 Topline safety (12 mos) Q3-2016: Rhopressa™ NDA filing expected Q4-2016: Rhopressa™ Rocket 4 Topline efficacy (3 mos) Q3-2016: Roclatan™ P3 Mercury 1 Topline efficacy (3 mos) Q2-2017: Roclatan™ P3 Mercury 2 Topline efficacy (3 mos) Q1-2016: Roclatan™ P3 Mercury 2 initiated |
 Building a Major Ophthalmic Pharmaceutical Company |